You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
萊美藥業(300006.SZ)擬共同設立Aglaea Pharma中國藥物有限公司
格隆匯 03-11 20:07

格隆匯3月11日丨萊美藥業(300006.SZ)公佈,為充分發揮Aglaea Pharma, Inc.(以下簡稱“Aglaea Pharma”)在多靶點小分子化合物篩選平台和疾病早期檢測、診斷技術開發平台構建的DNA編碼檢測抗體技術的創新優勢,公司擬與Aglaea Pharma、寧波星通厚勢投資合夥企業(有限合夥)(以下簡稱“星通厚勢”)共同簽署《投資協議》,共同發起設立Aglaea Pharma中國藥物有限公司(暫定名,以工商最後核名為準)(以下簡稱“合資公司”)。

合資公司初始註冊資本為人民幣1.125億元,同意公司以自有資金認繳出資額人民幣5000萬元。當滿足《投資協議》約定的後續投資先決條件後,合資公司認繳註冊資本增加至人民幣1.88億元,其中公司平價追加認購合資公司5000萬元註冊資本,屆時公司認繳出資額總額為1億元。投資完成後,公司在同等條件下對合資公司的目標知識產權的項目商業化擁有優先談判權。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account